Development Of An Endometrial Cancer Educational Tool

NCT07739745 — Not applicable, Not yet recruiting, 250 participants, M.D. Anderson Cancer Center

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT07739745
Status	Not yet recruiting
Phase	Not applicable
Study type	Interventional; non randomized, single group, masking: none, other
Enrollment	250 (Estimated)
Sponsor	M.D. Anderson Cancer Center (Other)
Conditions	Endometrial Cancer
Interventions	Interactive Educational Website (Other)
Dates	start 2027-01-01 (estimated), primary completion 2030-06-01 (estimated), completion 2032-06-01 (estimated), first posted 2026-07-31, last updated 2026-07-31
Locations	1 site in United States

-Summary

The goal of this study is to develop an online educational tool that we can make widely available to broader patient community.

Expand all sections · Collapse all

+Detailed description

Primary Objectives:

1. To develop an EC educational tool for systemic therapy of endometrial cancer.
2. To explore:

1. Acceptability of incorporating the EC educational tool into routine clinical care through a pilot study with EC patients
2. Feasibility, acceptability and the appropriateness of incorporating the EC educational tool into routine clinical care through a pilot study with health care providers of EC patients
3. To estimate the effectiveness of the EC educational tool with EC patients through a pilot study of EC patients and their health care providers.

+Arms and interventions

Arm	Type	Interventions	Description
Healthcare Providers	Experimental	Other: Interactive Educational Website	Healthcare providers will be recruited from MD Anderson Cancer Center and outside institutions to reflect a broad group of physicians
Patients	Experimental	Other: Interactive Educational Website	Participants will be recruited from the University of Texas MD Anderson Cancer Center (MDA), MDA Houston Area Locations (HALs), and The Harris Health System (LBJ).

Interactive Educational Website (Other): Participants will utilize website to access educational content, knowledge measure, values survey, and cognitive and usability testing

+Outcome measures

Primary outcomes

Safety and Adverse Events (AEs) [Through study completion; an average of 1 year]: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

+Eligibility

Sex: Female, ages: 18 Years to any

Inclusion Criteria:

Patients:

Study Objective 1 (Part A-C see Figure 2)

1. Women who have been diagnosed with endometrial cancer
2. Must be at least 18 years old
3. Must read and speak English or Spanish
4. Must provide written informed consent

Study Objectives 2 and 3 (Pilot Study)

1. Women who have been diagnosed with endometrial cancer who are or will be receiving systemic treatment
2. Must be at least 18 years old
3. Must read and speak English or Spanish
4. Must provide written informed consent.

Physicians:

Study Objective 1 (Qualitative Interviews)

1. Gynecologic oncologists or medical oncologists who practice at MDA or outside institutions
2. Must be able to speak and read English
3. Must provide written informed consent

Healthcare Providers:

Study Objectives 2 and 3 (Pilot Study)

1. Healthcare Providers (including but not limited to gynecologic oncologists and APPs) who practice at MDA, the HALs or LBJ Hospital who provide care to women diagnosed with endometrial cancer
2. Must be able to speak and read English
3. Must provide written informed consent

Exclusion Criteria:

None

+Locations (1)

Facility	City	Country	Status
UT MD Anderson	Houston, Texas	United States

+Investigators

Larissa Meyer, MD, MPH, Principal investigator, UT MD Anderson